Top Endovascular Robotic Systems Companies Driving the Future of Vascular Care

Endovascular robotics systems are computer-assisted and remotely operated technologies that provide stability, precision, and reduced exposure to radiation to patients undergoing minimally invasive vascular procedures. Increasingly prevalent cardiovascular conditions, surging volumes of surgical procedures, and the rise of hybrid operating rooms have resulted in widespread use of endovascular robotics systems in the marketplace. The growing aging population is also increasing the incidence of disorders, resulting in an increase in minimally invasive surgical procedures among patients, which ultimately contributes to the expanded use of endovascular robotics systems in the marketplace. A key trend is the transition from first generation robotic assistance to next-generation systems that are designed to be easier to use (smoother deployment with smaller footprints) and produce better clinical outcomes for patients. Manufacturers are also implementing strategic initiatives that involve integrating robotic systems with imaging systems, navigation systems, as well as possibly developing dedicated robotic systems for use during various types of surgery, including hybrid surgery.

Driven by these progressions in the industry, the market for endovascular robotic systems, projected by Fortune Business Insights, was valued at USD 1.36 billion in 2025. It is estimated to hit USD 4.04 billion by 2034, with a remarkable CAGR of 12.1% during the forecast period.

Fortune Business Insights Reveals Top 8 Endovascular Robotic Systems Companies Driving the Future of Vascular Care

1. Siemens Healthineers AG

Headquartered in Germany, Siemens Healthineers AG is a prominent manufacturer of medical technology with operations throughout the world, developing diagnostic and therapeutic imaging, laboratory diagnostic tools, and AI-enabled digital health solutions. Their solutions allow hospitals, clinics and research organizations globally to provide advanced and sustainable healthcare.

In August 2019, Siemens entered a merger agreement with Corindus Vascular Robotics, Inc., a pioneer in robotic-assisted vascular intervention technologies. The revolutionary technology has allowed to enhance the efficiency of procedures performed using image-guided minimally invasive therapies.

2. Microbot Medical, Inc.

Microbot Medical Inc. is headquartered in Massachusetts, U.S. The company focuses on transformative micro-robotic technologies, also maintains a research and development facility in Caesarea, Israel.  Microbot Medical Inc.’s LIBERTY Endovascular Robotic System announced that LIBERTY was introduced at the International Symposium on Endovascular Therapy (ISET) conference, which took place between February 9^th-12^th, 2026, in Miami Beach, Florida.

3. Stereotaxis, Inc.

Stereotaxic, Inc. is headquartered in Missouri, U.S., is a well-recognized global leader in innovative surgical robotics, specializing in minimally invasive endovascular procedures. The company also delivers, develops, and discovers several robotic systems, instruments, and solutions for laboratory.

Stereotaxis announced on November 17^th, 2023, that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new generation of Robotic Systems, called GenesisX™. GenesisX is the most recent evolution of robotic endovascular surgical systems, providing all of the benefits realized through Robotic Magnetic Navigation, and significantly improves accessibility for health care providers to deliver these therapies. The new GenesisX has, within its design, a more compact, efficient and flexible system than its predecessor.

4. Sentante

Headquartered in U.S., Sentante is a Lithuanian medical robotics company founded in 2017 that develops a, haptic, device-agnostic, teleoperated robot system for endovascular procedures. It allows surgeons to perform remote vascular interventions (e.g., stroke treatments) with real-time force feedback, protecting staff from radiation while maintaining precision.

In September 2025, Sentante announced that its robotic system has been accepted into the US Food and Drug Administration’s (FDA) Total Product Life Cycle Advisory Program (TAP). It provides selected medical device developers with early, frequent, and strategic engagement with the regulator and its partner agencies across the full product life cycle, from clinical development and regulatory strategy to market entry and post-market evidence generation.

5. Nanoflex Robotics AG

Nanoflex Robotics AG, headquartered in Switzerland, founded in 2021 as an ETH Zurich spin-out, develops advanced magnetic, soft-robotic systems for endovascular, neurovascular, and cardiovascular interventions. It is one of the top 8 endovascular robotic systems companies globally, aiming for the remote and telerobotic solutions for treating stroke patients by enhancing precision and access to care. In March 2024, Nanoflex Robotics AG, announced the introduction of its remote-ready robotics system for vascular interventions in North America of. The company installed the first system for neurovascular procedures at The Jacobs Institute, a nonprofit medical device innovation center in Buffalo, New York. The system will enable usability testing, in-vivo studies, and training. It will also serve as a site for physician demonstrations.

6. Remedy Robotics, Inc.

Remedy Robotics Inc. is an innovative medical technology company, which focuses on developing, manufacturing, and operating enhanced and remote-controlled endovascular robots. Its headquarter is located in the U.S. The company aims to democratize the access to life-saving, time-sensitive, and accurate cardiovascular and neuro-interventional process, including stroke treatment and stent placement.

On October 6^th, 2025, the company launched the Remedy N1 System as the world’s first endovascular robotic system for fully remote and AI-enabled neuro-interventional procedures. The system allows the surgeons to treat heart stroke and cardiovascular emergencies remotely, with the first in-human surgery successfully completed at Unity Health Toronto.

7. Robocath, Inc.

Founded in 2009 and headquartered in France, Robocath Inc. designs and markets enhanced robotic solutions for neurovascular and cardiovascular disease. Its product, R-One robotic platform improves procedural precision and protects medical staff from radiation.

In January 2026, Robocath launched the world’s first in-human clinical study evaluating its new robotic system in coronary artery disease. This advanced robot developed is installed in many centers around the world, implementing unprecedented and unrivaled capabilities to meet the increasing demands of complex coronary procedures,

8. XCath

Headquartered in Texas, U.S., XCath is a medical device company dedicated to pioneering neuro-endovascular surgical robotics. The company is known for developing innovative next-gen endovascular robotics, which specializes in expert navigation of the body’s blood vessels, improved clinical outcomes, and safer procedures with faster recovery.

In November 2025, Xcath announced the successful first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms. XCath’s EVR becomes the only endovascular robotic system currently in development that has achieved intracranial navigation or neurointerventional treatment. It is also the world’s first triaxial neurovascular robot to perform treatment.

Is Endovascular Robotics the Future of Minimally Invasive Vascular Care?

The advancements of robotic systems for the treatment of vascular disease are increasingly focused on utilizing Artificial Intelligence (AI) technology to create robotic solutions that operate autonomously, or as a part of a tele-robotic system. It also provides increased accuracy during procedures, significantly decrease patient exposure to radiation by 85% to 95%, and improve patient outcomes. Technologies such as haptic feedback, three-dimensional navigation, and compatibility with conventional instruments are being developed to facilitate safe robotic navigation through complex anatomy. AI technologies will support autonomous navigation of robotic systems to lesions in the body; above all, fully autonomous systems are anticipated to develop based on prior learning, from supervised, AI-assisted navigation using input from experienced operators. Haptic force feedback technology is now being incorporated into next generation robotic systems and offers real-time tactile feedback from the force placed on the robotic arm during the procedure; this haptic feedback will be critical for performing delicate neurovascular procedures. Several barriers slow down the development of robotic-assisted intervention becoming a standard of care for vascular treatment, including the high cost and limited compatibility of existing systems. However, the ultimate goal of the robotic-assisted intervention is to establish safer and more effective methods for treating vascular disease in the long term.